title: Comparison of effects on sleep of lovastatin and pravastatin in hypercholesterolemia.
abstract: The effects on sleep of lovastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor administered as a lipophilic lactone prodrug, and pravastatin, an inhibitor administered in its active, hydrophilic, open-acid form, were compared by polysomnographic sleep monitoring. Twenty-four men with primary hypercholesterolemia (low-density lipoprotein 4 to 7 mmol/liter) each received 2 of the following 3 treatments in a randomized, incomplete block, crossover design study: lovastatin (40 mg/day), pravastatin (40 mg/day), and placebo. Test drug was administered once daily for 4 weeks during each half of the crossover study. Subjective sleep assessments were obtained throughout each treatment period, and polysomnographic recordings were obtained at the end of the 4-week treatment periods. Treatment periods were separated by a 1-week washout. Lovastatin did not differ from placebo regarding any polysomnographic parameter except "number of entries to wake," for which it produced fewer entries (i.e., change was in the direction of improvement). Pravastatin did not differ from placebo regarding any polysomnographic measures, but was associated with worsening in relation to lovastatin in the following parameters: sleep efficiency, entries to wake, percent rapid eye movement sleep, wake time during sleep, and total wake time. For each of these 4 parameters, although neither drug showed marked differences from placebo, the mean change in the lovastatin group was in the direction of improved sleep, whereas the change in the pravastatin group was in the direction of disturbed sleep. Neither lovastatin nor pravastatin had any effect on subjective, qualitative sleep ratings.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Ullanlinna Sleep Disorders Clinic and Research Center, Helsinki, Finland.
authors.forename: M
authors.initials: M
authors.lastname: Partinen
authors.forename: S
authors.initials: S
authors.lastname: Pihl
authors.forename: T
authors.initials: T
authors.lastname: Strandberg
authors.forename: H
authors.initials: H
authors.lastname: Vanhanen
authors.forename: E
authors.initials: E
authors.lastname: Murtomäki
authors.forename: G
authors.initials: G
authors.lastname: Block
authors.forename: R
authors.initials: R
authors.lastname: Neafus
authors.forename: J
authors.initials: J
authors.lastname: Haigh
authors.forename: T
authors.initials: T
authors.lastname: Miettinen
authors.forename: S
authors.initials: S
authors.lastname: Reines
mesh_terms: D000328:Adult; D000368:Aged; D004311:Double-Blind Method; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy* / Q000503:physiopathology; D008074:Lipoproteins / Q000097:blood; D008148:Lovastatin / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D017286:Polysomnography; D017035:Pravastatin / Q000009:adverse effects / Q000627:therapeutic use*; D012890:Sleep / Q000187:drug effects*
chemical_list: D008074:Lipoproteins; D008148:Lovastatin; D017035:Pravastatin